A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma

Journal of Pathology

Volumn 234, Issue 2, 2014, Pages 228-238

  Yamaguchi, Takashi ^a   Ikehara, Sanae ^a   Nakanishi, Hayao ^b   Ikehara, Yuzuru ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Genetically engineered mouse model; KrasG12D; Temperature sensitive T antigen

Indexed keywords

K RAS PROTEIN; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN; VIRUS LARGE T ANTIGEN; PROTEIN P21; VIRUS T ANTIGEN;

3T3 CELL LINE; ACINAR CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; DISEASE COURSE; EPITHELIUM CELL; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREATIC CANCER CELL LINE; PHENOTYPE; RAT; SIMIAN VIRUS 40; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL TRANSFORMATION; DISEASE MODEL; GENETICALLY ENGINEERED MOUSE MODEL; GENETICS; HUMAN; KRASG12D; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TEMPERATURE-SENSITIVE T ANTIGEN; TRANSGENIC MOUSE; TUMOR CELL LINE;

GENETICALLY ENGINEERED MOUSE MODEL; KRASG12D; TEMPERATURE-SENSITIVE T ANTIGEN;

ANIMALS; ANTIGENS, VIRAL, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907955460     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4402     Document Type: Article

References (48)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Real FX. A 'catastrophic hypothesis' for pancreas cancer progression. Gastroenterology 2003; 124: 1958-1964.
3. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011; 378: 607-620.
4. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-1249.
5. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006; 66: 95-106.
6. Reichert M, Rustgi AK. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 2011; 121: 4572-4578.
7. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-3126.
8. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483.
9. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947-5952.
10. Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006; 20: 3130-3146.
11. Carriere C, Gore AJ, Norris AM, et al. Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology 2011; 141: 1091-1101.
12. Hill R, Calvopina JH, Kim C, et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 2010; 70: 7114-7124.
13. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9: 738-748.
14. Rassoulzadegan M, Naghashfar Z, Cowie A, et al. Expression of the large T protein of polyoma virus promotes the establishment in culture of 'normal' rodent fibroblast cell lines. Proc Natl Acad Sci USA 1983; 80: 4354-4358.
15. Dyson N, Bernards R, Friend SH, et al. Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J Virol 1990; 64: 1353-1356.
16. Hannon GJ, Demetrick D, Beach D. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes Dev 1993; 7: 2378-2391.
17. DeCaprio JA, Ludlow JW, Figge J, et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988; 54: 275-283.
18. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
19. Krieg P, Amtmann E, Jonas D, et al. Episomal simian virus 40 genomes in human brain tumors. Proc Natl Acad Sci USA 1981; 78: 6446-6450.
20. Linzer DI, Levine AJ. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52.
21. McCormick F, Harlow E. Association of a murine 53 000 Dalton phosphoprotein with simian virus 40 large-T antigen in transformed cells. J Virol 1980; 34: 213-224.
22. Jat PS, Sharp PA. Cell lines established by a temperature-sensitive simian virus 40 large-T-antigen gene are growth restricted at the nonpermissive temperature. Mol Cell Biol 1989; 9: 1672-1681.
23. Jat PS, Noble MD, Ataliotis P, et al. Direct derivation of conditionally immortal cell lines from anH-2Kb-tsA58 transgenic mouse. Proc Natl Acad Sci USA 1991; 88: 5096-5100.
24. Yamaguchi T, Ichise T, Iwata O, et al. Development of a new method for isolation and long-term culture of organ-specific blood vascular and lymphatic endothelial cells of the mouse. FEBS J 2008; 275: 1988-1998.
25. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
26. Hingorani SR, Petricoin EF,Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
27. Ikehara Y, Niwa T, Biao L, et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res 2006; 66: 8740-8748.
28. Sato T, Kudo T, Ikehara Y, et al. Chondroitin sulfate N-acetylgalactosaminyltransferase 1 is necessary for normal endochondral ossification and aggrecan metabolism. J Biol Chem 2011; 286: 5803-5812.
29. Ikehara Y, Ikehara SK, Paulson JC. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem 2004; 279: 43117-43125.
30. Ornitz DM, Hammer RE, Messing A, et al. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 1987; 238: 188-193.
31. HanahanD.Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315: 115-122.
32. WescottMP, Rovira M, ReichertM, et al. Pancreatic ductal morphogenesis and the Pdx1 homeodomain transcription factor. Mol Biol Cell 2009; 20: 4838-4844.
33. Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290-1295.
34. Takeuchi Y, Nakao A, Harada A, et al. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 1993; 88: 1928-1933.
35. Sipos B, Hahn D, Carceller A, et al. Immunohistochemical screening for β6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 2004; 45: 226-236.
36. Li A, Omura N, Hong SM, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010; 70: 5226-5237.
37. Mazur PK, Siveke JT. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut 2011; 61: 1488-1500.
38. Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010; 10: 683-695.
39. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut 2011; 61: 449-458.
40. Ceci JD, Kovatch RM, Swing DA, et al. Transgenic mice carrying a murine amylase 2.2/SV40 T antigen fusion gene develop pancreatic acinar cell and stomach carcinomas. Oncogene 1991; 6: 323-332.
41. Sutherland KD, Proost N, Brouns I, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011; 19: 754-764.
42. Ho VM, Schaffer BE, Karnezis AN, et al. The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-ras. Oncogene 2009; 28: 1393-1399.
43. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120: 513-522.
44. Caldwell ME, Denicola GM, Martins CP, et al. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene 2011; 31: 1599-1608.
45. Guerra C, ColladoM, Navas C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011; 19: 728-739.
46. Kennedy AL, Morton JP, Manoharan I, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011; 42: 36-49.
47. McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta 2008; 1782: 127-150.
48. Javier RT, Butel JS. The history of tumor virology. Cancer Res 2008; 68: 7693-7706.